BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei YJ, Hsu PY, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group. J Viral Hepat 2021;28:719-27. [PMID: 33533547 DOI: 10.1111/jvh.13477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Reference Citation Analysis]
2 Su PY, Su WW, Hsu YC, Wang SY, Chiu PF, Yen HH. Micro-Elimination of Hepatitis C among Patients with Kidney Disease by Using Electronic Reminder System-A Hospital-Based Experience. J Clin Med 2022;11:423. [PMID: 35054120 DOI: 10.3390/jcm11020423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang CF, Wei YJ, Wu YT, Chiu YW, Yu ML. Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy. J Hepatol 2021;75:1006-7. [PMID: 34051333 DOI: 10.1016/j.jhep.2021.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]